NASDAQ:AERI Aerie Pharmaceuticals (AERI) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.25▼$15.2550-Day Range$15.18▼$15.2552-Week Range$4.81▼$15.37Volume600 shsAverage Volume974,748 shsMarket Capitalization$753.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability About Aerie Pharmaceuticals (NASDAQ:AERI) StockAerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.Read More AERI Stock News HeadlinesSeptember 25, 2023 | uk.finance.yahoo.comRising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment MarketSeptember 13, 2023 | benzinga.comOptic Nerves Disorder Treatment Market Rises: North America Takes the HelmSeptember 26, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 25, 2023 | time.comAerie Promo CodesAugust 24, 2023 | uk.finance.yahoo.comAngina Pectoris Drugs Global Market Report 2023August 24, 2023 | uk.finance.yahoo.comOcular Hypertension Treatment Global Market Report 2023July 18, 2023 | msn.comAlcon (ALC) Gains From Robust Contact Lense Sales, LaunchesJune 27, 2023 | finance.yahoo.comVillageMD Welcomes Richard Rubino as Chief Financial OfficerSeptember 26, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.June 22, 2023 | marketwatch.comThe Glaucoma Therapeutics market's size, share, and revenue will be thoroughly examined, with an anticipated CAGR of 13% increase from 2023 to 2030.June 22, 2023 | uk.finance.yahoo.comI-Mab Announces the Appointment of Raj Kannan as CEOJune 22, 2023 | markets.businessinsider.comI-Mab Names Raj Kannan CEO - Quick FactsJune 8, 2023 | uk.finance.yahoo.comOphthalmic Drugs Global Market Report 2023May 17, 2023 | msn.comAlcon (ALC) Vision Care Sales Robust, Margin Pressure PersistsMay 17, 2023 | marketwatch.comGlaucoma Therapeutics Market Size and Growth Analysis 2023-2031 by Absolute Reports with [121 Pages] in Pharmaceuticals SectorMay 17, 2023 | marketwatch.comOptic Nerves Disorder Treatment Market Size Fundamentals And Forecast Analysis 2023-2030May 16, 2023 | marketwatch.comOphthalmology Therapeutics Market 2023: Global Opportunity Analysis by Revenue, Gross Margin, Market ShareMay 5, 2023 | marketwatch.com2030 Vision: Ophthalmology Drugs Market Value to Hit New HeightsMay 5, 2023 | marketwatch.comAnophthalmia and Microphthalmia Treatment Market Share, Size and Value Analysis with growing 5.3% CAGR during period 2023 to 2030May 4, 2023 | marketwatch.comGlaucoma Therapeutics Market Trend Analysis, Future Demand, Updates (2023-2030)May 4, 2023 | marketwatch.comRho Kinases Inhibitor Market 2023 Precise Outlook – Kowa Pharmaceuticals, Senju Pharmaceutical, Novartis AG, AERIE PHARMACEUTICALSMay 2, 2023 | uk.news.yahoo.comMindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing StrategyMay 2, 2023 | marketwatch.comGlaucoma Treatment Market Upcoming Trends, Size, Key Players, Revenue, Share, and Forecast 2023 to 2031April 28, 2023 | marketwatch.comWave-Front Aberrometer Market Research 2023 Growth, Trends, Outlook and Future Scope Analysis 2031April 27, 2023 | marketwatch.comGlaucoma and Dry Eye Diseases Market Research Analysis 2023-2031April 27, 2023 | marketwatch.com2023 to 2030, Rho Associated Protein Kinase 2 Market DemandApril 26, 2023 | thestreet.comAerie Pharma Falls on Glaucoma Eye Drop Safety ConcernsSee More Headlines Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AERI Company Calendar Last Earnings11/04/2021Today9/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AERI CUSIPN/A CIK1337553 Webwww.aeriepharma.com Phone(919) 237-5300Fax949-526-8787Employees376Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,810,000.00 Net Margins-17.09% Pretax Margin-16.47% Return on EquityN/A Return on Assets-2.00% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio1.92 Sales & Book Value Annual Sales$194.13 million Price / Sales3.88 Cash FlowN/A Price / Cash FlowN/A Book Value($3.32) per share Price / Book-4.59Miscellaneous Outstanding Shares49,417,000Free Float47,223,000Market Cap$753.61 million OptionableOptionable Beta-0.06 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Raj Kannan (Age 58)CEO, Principal Financial Officer & Director Comp: $753.49kDr. Casey C. Kopczynski Ph.D. (Age 61)Co-Founder, Chief Innovation Officer & Head of Research and External Innovation Comp: $685.06kMr. John W. LaRocca Esq. (Age 57)Gen. Counsel & Sec. Comp: $676.62kMr. Peter F. Lang (Age 50)Chief Financial Officer Dr. Michelle Senchyna Ph.D.Head of Clinical Devel. & OperationsMr. Jeffrey M. Calabrese CPA (Age 55)VP of Fin. & Principal Accounting Officer Ms. Carolyn McAuliffeSr. Director of CommunicationsMs. Wanda FranciesHead of HRMr. Marvin J. Garrett (Age 71)Head of Regulatory Affairs & Quality Assurance Mr. Craig R. SkenesHead of Bus. Devel.More ExecutivesKey CompetitorsNovavaxNASDAQ:NVAXAdaptimmune TherapeuticsNASDAQ:ADAPAdaptive BiotechnologiesNASDAQ:ADPTREGENXBIONASDAQ:RGNXAmbrx BiopharmaNYSE:AMAMView All Competitors AERI Stock - Frequently Asked Questions How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its earnings results on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.10. The firm earned $29.31 million during the quarter, compared to the consensus estimate of $29.13 million. During the same period in the previous year, the company earned ($0.65) EPS. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA). What is Aerie Pharmaceuticals' stock symbol? Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI." What is Aerie Pharmaceuticals' stock price today? One share of AERI stock can currently be purchased for approximately $15.25. How much money does Aerie Pharmaceuticals make? Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $753.61 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. How many employees does Aerie Pharmaceuticals have? The company employs 376 workers across the globe. How can I contact Aerie Pharmaceuticals? Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787. This page (NASDAQ:AERI) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerie Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.